Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (NASDAQ: LTRN) generates a steady flow of news as an AI-driven, clinical-stage oncology company advancing both a precision medicine pipeline and a proprietary artificial intelligence platform. News coverage on this page centers on developments in its RADR® AI and machine learning platform, clinical trial milestones for LP-184, LP-284, and LP-300, regulatory interactions, and strategic initiatives that shape the company’s position in AI-enabled cancer drug development.
Investors and researchers following LTRN news will find detailed updates on Phase 1 and Phase 2 clinical trials, including safety and efficacy readouts, biomarker findings, and disease control observations in heavily pre-treated cancer patients. Recent announcements have highlighted LP-184’s Phase 1a results in advanced solid tumors, LP-284’s activity in relapsed or refractory B-cell lymphomas, and LP-300 data from the HARMONIC™ trial in never-smoker non-small cell lung cancer. Lantern also reports on FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease status that influence development pathways for its drug candidates.
In addition to clinical results, Lantern’s news stream covers the evolution of its RADR® platform and related AI modules. Articles describe the launch and performance of tools like predictBBB.ai for blood–brain barrier prediction and LBx-AI for liquid biopsy-based treatment response modeling, as well as presentations at scientific meetings and symposia. Corporate news items include quarterly financial updates, at-the-market financing agreements, board appointments, proxy statements, and the announcement of an AI Center of Excellence in Bengaluru, India to scale RADR® and multi-agent AI systems for global biopharma partners.
By reviewing the LTRN news feed, readers can track how Lantern integrates AI, genomics, and clinical data into its oncology programs, how regulators and collaborators engage with its pipeline, and how the company positions its AI modules and partnerships in the broader biopharmaceutical landscape. This page is a resource for monitoring material events, clinical inflection points, and platform advances that Lantern discloses through press releases and regulatory communications.
Lantern Pharma Inc. (NASDAQ: LTRN) announced significant findings at the SABCS 2022, highlighting the promising anti-tumor effects of its drug candidate LP-184 against Triple Negative Breast Cancer (TNBC). LP-184 demonstrated an average IC50 of 297nM across four TNBC cell lines and achieved a remarkable 107-141% tumor regression in 10 resistant tumor models. The annual market for TNBC represents approximately $1.7 billion USD. The expansion of LP-184's indications may enhance its long-term value and address unmet needs in solid tumors.
Lantern Pharma (NASDAQ: LTRN) announced that CEO Panna Sharma will present at the RHK Capital Disruptive Growth Conference in New York City on December 5, 2022, at 12:00 p.m. ET. This conference will showcase around 30 innovative companies, connecting them with institutional and accredited investors.
Lantern Pharma leverages its RADR® AI platform for oncology drug development, focusing on genomically-targeted therapies, with four candidates in progress.
Lantern Pharma (NASDAQ: LTRN) announced positive preclinical data for its drug candidate LP-184 targeting glioblastoma (GBM) at the Society for Neuro-Oncology annual meeting. The study showed LP-184's efficacy either alone or combined with spironolactone, outperforming the standard treatment Temozolomide (TMZ) in resistant models. LP-184 has the potential market of $1.5-2.0 billion, with ongoing collaborative research with Johns Hopkins aimed at advancing it to clinical trials in 2023. The drug holds Orphan Drug and Rare Pediatric Disease designations, emphasizing its potential in oncology.
Lantern Pharma (NASDAQ: LTRN) reported third quarter results for 2022, activating two sites for the Harmonic™ clinical trial in never-smoker patients with NSCLC. The completion of IND-enabling studies for LP-184 and LP-284 is anticipated in Q1 2023, with Phase 1 trials planned for H1 2023. As of September 30, 2022, Lantern held $57.8 million in cash, reflecting a net decrease of $4.3 million during the quarter. Despite a net loss of $2.3 million, a significant reduction from $4.1 million year-over-year, the company maintains a cash runway into 2025.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its participation in two investor conferences. The BioFuture Conference will take place in New York, NY on November 8, 2022, with presentations by CEO Panna Sharma and CFO David Margrave at 2:00 p.m. ET. The Disruptive Growth Conference is set for December 5-6, 2022, with the time for Sharma's presentation to be announced. Lantern Pharma is advancing oncology drug discovery through its proprietary RADR® platform, targeting customized therapeutics for diverse tumor profiles.
Lantern Pharma Inc. (NASDAQ: LTRN) will host its third quarter 2022 financial results webcast on November 7, 2022 at 4:30 p.m. ET. The management, led by CEO Panna Sharma, will discuss the operating and financial results from the third quarter ended September 30, 2022, alongside future milestones. Lantern Pharma focuses on oncology drug discovery using its proprietary RADR® A.I. platform to identify patient populations likely to benefit from its drug candidates, including four candidates and an ADC program across nine tumor targets.
Lantern Pharma (NASDAQ: LTRN) announced it will present new preclinical data at three scientific conferences: the Society of Neuro Oncology Annual Meeting on November 18, the San Antonio Breast Cancer Symposium on December 8, and the American Society of Hematology Annual Meeting on December 10. A key focus will be the preclinical efficacy of LP-184, a therapeutic targeting glioblastoma. Lantern Pharma leverages its proprietary RADR® platform to identify patients likely to benefit from its targeted therapies, which could significantly enhance treatment outcomes.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its participation in the ThinkEquity Conference on October 26, 2022, in New York, NY. Lantern's CEO, Panna Sharma, is set to host an A.I. and Drug Development Panel at 10:00 a.m. ET, discussing the role of A.I. in enhancing oncology drug development. Lantern is scheduled to present at 1:00 p.m. ET, with a webcast available for viewers. The company aims to leverage its RADR® A.I. platform to optimize drug discovery and development timelines.
Lantern Pharma (NASDAQ: LTRN) has secured U.S. Patent No. 11,471,431 for its drug candidate LP-300, aimed at enhancing survival in cancer patients with overexpressed thioredoxin or glutaredoxin. This patent extends commercial protection until late 2032, fostering potential partnerships and new cancer treatment programs. LP-300 is currently in a Phase 2 clinical trial for relapsed non-small cell lung cancer (NSCLC) patients. The drug has previously shown significant survival improvements in clinical trials.
Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharmaceutical company, is set to present at the MicroCap Rodeo Windy City Roundup 2022 on October 12 at 11:00 a.m. ET. CEO Panna Sharma will lead the presentation, which will be live-streamed and available for replay. Lantern Pharma leverages its proprietary RADR® platform for oncology drug discovery, focusing on developing targeted therapeutics based on patient genomic profiles. Attendees can schedule one-on-one meetings with the management team throughout the event.